NuLife CBD

October 24th, 2019

When it comes to the health benefits of CBD, it is often the case that the science says one thing and the marketing says another.

Take cancer. According to the National Cancer Institute (NCI), cannabinoids in the cannabis plant like non-high-inducing CBD may help treat the side effects of cancer. But clinical trials that study cannabis for cancer treatment are limited and there are no such ongoing studies in a vast database of more than 30 million citations maintained by the National Institutes of Health, NCI says.

You can’t rush the science. Yet many marketers of CBD products including, until recently, NuLife, tout their CBD-infused capsules, oils and creams as a proven treatment for cancer, among other serious diseases. It seems it’s not until they are faced with the threat of legal action that they begin to tighten up their marketing.

Such was the fate of NuLife, which, after receiving an FTC warning letter last month, made extensive edits to a medical applications page on its website that had recommended CBD for everything from cancer to Alzheimer’s disease to autism. These claims are gone.

In addition, other language has been toned down. For example, where NuLife used to refer to the “health applications of CBD,” the company now cites the “possible benefits of CBD.” However, in another section of the website, NuLife still carries three product reviews that claim the company’s creams and oils help with arthritis and high blood pressure, despite the FTC flagging the reviews in its letter, which warned:

It’s not enough that an endorsement represents the consumer’s honest opinion or experience. Reasonable consumers may interpret an endorsement claiming a health benefit from the use of a product as representing that the product is likely to be effective in achieving that benefit. Under FTC law, an advertiser must possess and rely on competent and reliable scientific evidence to support health claims, both express and implied, made through the use of endorsements.

The FTC also sent warning letters to the marketers of Ocanna and Magic Green Oil Drops CBD products. TINA.org obtained the letters through a Freedom of Information Act request.

Read more about our coverage on CBD here.

Print Friendly, PDF & Email

Tags: ,



One Response to NuLife CBD

  1. Dina M. says:

    NuLife CBD Oils takes the safety and transparency of NuLife products, and CBD in general, very seriously. We have always included recommendations to talk to doctors prior to using CBD. We state right on our web page that the FDA is still reviewing uses of CBD as a health supplement and treatment for specific ailments. We do acknowledge that CBD has been used by our society for centuries and we have noted areas that show great promise and state it in that manner. We also post our customer reviews, where several clients had stated their success with managing specific ailments. We were contacted by the FTC in October asking us to remove these statements, as they might mislead users to believe CBD could do something that the FDA had not yet proven. We have worked with the FTC to ensure that our website is now in full compliance with their requirements and we’ll continue to work with them in this positive manner.

    We were surprised that a site called “Truth in Advertising” would post such an inflammatory article against a company without reaching out to that company first, in an effort to present a fair account of a situation. Especially given the fact that the federal government is the cause of the product ban, resulting in limited research for decades and now that the ban has been lifted, they are in charge of the discussions around said product. Seems very one sided, and this site has perpetuated that view point. Truth in Advertising could be such a useful resource if it they put in a little time to be more balanced and present a full picture to readers.

Leave a Reply

Back to Top ↑